Received 20200627 Accepted 20200824 Available online 20200916 Published 20201108 Identification Prognostic Value Clinical Significance Interferon Regulatory Factors IRFs Colon Adenocarcinoma eISSN 16433750 Med Sci Monit 2020 26 e927073 DOI 1012659MSM927073 Authors Contribution Study Design A Data Collection B Statistical Analysis C Data Interpretation D Manuscript Preparation E Literature Search F Funds Collection G ABCDEF 1 Munire Yuemaier AEFG 1 Zhiqiang Zhou ABCDE 2 Youxu Zhou CDE 1 Chengwen Wu CDEF 1 Fei Li BCEF 1 Xiaodan Liang BCDEF 1 Haihan Kang FG 1 Dongfang Shen EFG 1 Fei Gao Jinxi Lin E 2 1 Department General Surgery The Second Affiliated Hospital Zhengzhou University Zhengzhou Henan PR China 2 Department General Surgery The Third Affiliated Hospital Fujian Traditional Chinese Medical University Fuzhou Fujian PR China Corresponding Author Source support Munire Yuemaier Zhiqiang Zhou equal contribution Jinxi Lin email 357653176qqcom Key Science Technology Foundation Henan Province No 122102310239 Guided Project Key Topics Fujian Province Endoscopic injection marking method advanced treatment colorectal cancer precision No 2018Y0066 Henan Health Science Technology Innovative Talent Funding Project No 201004121 Background MaterialMethods Results Conclusions Colon adenocarcinoma COAD common malignant tumors high incidence mor tality rates The interferon regulatory factor IRF family known key transcription factor IFN signal ing pathway cellular immunity This research explored relationship IRF family COAD use bioinformatics technology Using UALCAN GEPIA databases analyzed transcription prognostic value IRFs COAD GSCALite cancer genomics analysis TIMER LinkedOmics Metascape assess potential function IRFs COAD The transcription levels IRF3 elevated COAD tissues IRF246 downregulated compared normal patients subgroup analyses race age weight sex nodal metastasis individual cancer stag es TP53 mutation status histological subtypes IRF3 IRF7 COAD significantly associated poor prognosis Drug sensitivity analysis revealed expression level IRF248 negatively asso ciated drug resistance A significant correlation IRF family immune cell infil tration Moreover enrichment analysis revealed IRFs associated response tumor necrosis factor transcription misregulation cancer JAKSTAT signaling pathway We identified kinase miRNA targets IRF family COAD We identified IRF3 IRF7 prognostic biomarkers COAD IRF family associated immune cell infiltration gene regulation networks providing additional evidence showing significant role IRF family COAD MeSH Keywords Biological Markers Colorectal Neoplasms Interferon Regulatory Factors Fulltext PDF httpswwwmedscimonitcomabstractindexidArt927073 2879 6 11 33 e9270731 Indexed Current ContentsClinical Medicine SCI Expanded ISI Alerting System ISI Journals Master List Index MedicusMEDLINE EMBASEExcerpta Medica Chemical AbstractsCASThis work licensed Creative Common AttributionNonCommercialNoDerivatives 40 International CC BYNCND 40DATABASE ANALYSIS Yuemaier M et al The role IRFs COAD Med Sci Monit 2020 26 e927073 Background Colon adenocarcinoma COAD high incidence rate common adenocarcinoma worldwide High risk groups include people older 50 years fam ily history hereditary familial polyposis younger patients unfortunately tend diagnosed advanced stage COAD To identify patients quickly easily reliable biomarkers needed pre dict disease status prognosis In 2018 18 million new colon cancer cases 880 000 COAD related deaths Notably disease beginning develop younger age 12 Despite decreased incidence COADrelated deaths improvements early tection screening programs including endoscopy fecal occult blood testing patients continue present advanced disease 3 Molecular markers carcinoem bryonic antigen CEA carbohydrate antigen 199CA19 9 COAD diagnosis However patients COAD stages continue die disease 45 Therefore exploring reliable biomarkers early pathological chang es molecular mechanism crucial early di agnosis overall survival prediction treatment effect tar geted therapy development Interferon regulatory factors IRFs belong family tran scription factors include IRF1IRF9 members hu mans mice They known critical roles adap tive immunity 6 Nonetheless expressed tissue cells immune cells Accumulating evidence indicates IRFs crucially function cell differentiation apopto sis cell cycle immunological regulation asso ciated tumor progression 78 Studies shown IRFs involved tumorigenesis activating tumorrelat ed gene transcription 9 For instance elevated expres sion level IRF2 cancer cells promotes activity NFkB delivery activators TNFa By enhanc ing activity NFkB carcinogenic potential IRF2 increased 10 However differences expression levels molecular mechanisms genetic variations prog nostic significance IRFs COAD thor oughly studied In present study performed bioinfor matics analysis public databases including ULACAN GEPIA TCGA TIMER explore correlation IRF fam ily members COAD Material Methods Datasets A total 286 COAD patients enrolled The Cancer Genome Atlas TCGA dataset None received form chemoradiotherapy We assessed IRFs mRNA level following bioinformatics portals UALCAN UALCAN httpualcanpathuabedu evaluation differences IRF expression profiles COAD healthy tissues TCGA COAD dataset n 286 This site analyzes relative expression target genes tu mor normal samples including analysis tumor sub groups based individual cancer stage tumor grade oth er clinicopathologic features 11 Using functions assessed relationship IRFs expression level patient survival t test P005 considered sta tistically significant GEPIA We online database Gene Expression Profiling Interactive Analysis GEPIA httpgepiacancerpkucnin dexhtml webbased tool deliver gene expression corre lation analysis data based TCGA The functions GEPIA provides include correlation analysis patient survival analysis profiling plotting 12 Through use data base assessed correlations expression lev el IRFs diseasefree survival DFSoverall survival OS COAD The 10 genes correlated IRFs member COAD analyzed Spearman correlation test P005 considered statistically significant GSCALite GSCALite httpbioinfolifehusteducnwebGSCALite pro vides methylation module establish IRFs methylation level COAD 13 The t test define differences methylation tumor normal samples We tested association paired mRNA expression methyl ation based Pearsons productmoment correlation coeffi cient follows t distribution P values adjusted FDR FDR 005 considered significant Moreover singlenucleotide variation SNV frequency variant types IRFs COAD association IRF family drug sensitivity explored The SNV summary oncoplot waterfall plot generated maftools 14 TIMER The Tumor Immune Estimation Resource TIMER cistrome shinyappsiotimer public web resource infer abundance tumorinfiltrating immune cells TIICs gene expression profiles The 6 major analytic modules includ ing gene expression clinical outcomes somatic mutations They enable users analyze correlation immune This work licensed Creative Common Attribution NonCommercialNoDerivatives 40 International CC BYNCND 40 e9270732 Indexed Current ContentsClinical Medicine SCI Expanded ISI Alerting System ISI Journals Master List Index MedicusMEDLINE EMBASEExcerpta Medica Chemical AbstractsCASDATABASE ANALYSIS Yuemaier M et al The role IRFs COAD Med Sci Monit 2020 26 e927073 A n o l l m r e p t p r c s n r T D n o l l m r e p t p r c s n r T 250 200 150 100 50 0 20 15 10 5 0 5 G n o l l m r e p t p r c s n r T 60 50 40 30 20 10 0 10 Expression IRF1 COAD based sample types P0179 Normal n41 Primary rtumor n286 TCGA sample n o l l m r e p t p r c s n r T B 60 50 40 30 20 10 0 E Expression IRF2 COAD based sample types P439E12 Normal n41 Primary rtumor n286 TCGA sample C n o l l m r e p t p r c s n r T 125 100 75 50 25 0 F Expression IRF3 COAD based sample types P162E12 Normal n41 Primary rtumor n286 TCGA sample Expression IRF41 COAD based sample types Expression IRF5 COAD based sample types Expression IRF6 COAD based sample types P155E12 Normal n41 Primary rtumor n286 TCGA sample Expression IRF47 COAD based sample types P501E03 Normal n41 Primary rtumor n286 TCGA sample 20 15 10 5 0 5 n o l l m r e p t p r c s n r T H 100 n o l l m r e p t p r c s n r T 80 60 40 20 0 20 P0160 Normal n41 Primary rtumor n286 TCGA sample 70 60 50 40 30 20 10 0 n o l l m r e p t p r c s n r T I P856E04 Normal n41 Primary rtumor n286 TCGA sample Expression IRF8 COAD based sample types Expression IRF9 COAD based sample types P0236 Normal n41 Primary rtumor n286 TCGA sample n o l l m r e p t p r c s n r T 150 125 100 75 50 25 0 P0311 Normal n41 Primary rtumor n286 TCGA sample Figure 1 AI The expression level IRFs COAD normal tissues ULCAN The transcriptional level IRF3 substantially upregulated COAD tissues relative normal tissues P005 considered statistically significant infiltrations factors 15 In present study IRFs expression correlated abundance immune cell infiltrates COAD assessed gene module results displayed scatter plots Furthermore com pare TIICs abundance COAD different copy number dis tortions IRF family SCNA modules TIIC subset box plot generated compare distri bution abundance TIICs different gene muta tion status statistical significance estimated twosided Wilcoxon ranksum test This analysis formed based TCGA COAD dataset n286 P005 considered statistically significant LinkedOmics LinkedOmics httpwwwlinkedomicsorg includes multiomics data clinical data 32 cancer types TCGA data set 16 We performed kinase target enrichment miRNA target enrichment IRF family COAD The results graphically presented volcano plots heat maps scatter plots The rank criterion minimum number genes size 9 simulation 500 P005 consid ered statistically significant e9270733 Indexed Current ContentsClinical Medicine SCI Expanded ISI Alerting System ISI Journals Master List Index MedicusMEDLINE EMBASEExcerpta Medica Chemical AbstractsCASThis work licensed Creative Common AttributionNonCommercialNoDerivatives 40 International CC BYNCND 40DATABASE ANALYSIS Yuemaier M et al The role IRFs COAD Med Sci Monit 2020 26 e927073 Expression IRF2 COAD based patients weight Expression IRF2 COAD based patients gender A n o l l m r e p t p r c s n r T n o l l m r e p t p r c s n r T B n o l l m r e p t p r c s n r T n o l l m r e p t p r c s n r T 60 50 40 30 20 10 0 60 50 40 30 20 10 0 150 125 100 75 50 25 0 150 125 100 75 50 25 0 Expression IRF2 COAD based patients race Normal n41 Caucasian n193 African American n55 Asian n11 TCGA sample Expression IRF2 COAD based nodal metastasis status Normal n41 N0 n166 N1 n70 N2 n47 n o l l m r e p t p r c s n r T n o l l m r e p t p r c s n r T 60 50 40 30 20 10 0 60 50 40 30 20 10 0 Expression IRF2 COAD based patients age Normal n41 2140 Yrs n12 4160 Yrs n90 6180 Yrs n149 81100 Yrs n32 TCGA sample Expression IRF2 COAD based individual cancer stages Normal n41 Stage1 n45 Stage2 n120 Stage3 n80 Stage4 n39 n o l l m r e p t p r c s n r T n o l l m r e p t p r c s n r T 60 50 40 30 20 10 0 60 50 40 30 20 10 0 Normal n41 Normal weight n70 Extreme weight n74 TCGA sample Obese n56 Extreme obese n10 Expression IRF2 COAD based TP53 muation status Normal n41 TP53Mutast n160 TP53NonMutant n122 TCGA sample TCGA sample TCGA sample Expression IRF3 COAD based patients race Expression IRF3 COAD based patients age Expression IRF3 COAD based patients weight Normal n41 Caucasian n193 African American n55 Asian n11 TCGA sample Expression IRF3 COAD based nodal metastasis status Normal n41 N0 n166 N1 n70 N2 n47 n o l l m r e p t p r c s n r T n o l l m r e p t p r c s n r T 150 125 100 75 50 25 0 125 100 75 50 25 0 Normal n41 2140 Yrs n12 4160 Yrs n90 6180 Yrs n149 81100 Yrs n32 TCGA sample Expression IRF3 COAD based individual cancer stages Normal n41 Stage1 n45 Stage2 n120 Stage3 n80 Stage4 n39 n o l l m r e p t p r c s n r T n o l l m r e p t p r c s n r T 150 125 100 75 50 25 0 120 100 80 60 40 20 Normal n41 Normal weight n70 Extreme weight n74 TCGA sample Obese n56 Extreme obese n10 Expression IRF3 COAD based TP53 muation status Normal n41 TP53Mutast n160 TP53NonMutant n122 TCGA sample TCGA sample TCGA sample n o l l m r e p t p r c s n r T n o l l m r e p t p r c s n r T n o l l m r e p t p r c s n r T n o l l m r e p t p r c s n r T 60 50 40 30 20 10 0 60 50 40 30 20 10 0 125 100 75 50 25 0 120 100 80 60 40 20 Normal n41 Male n156 Female n127 TCGA sample Expression IRF2 COAD based histological subtypes Normal n41 Adenocarcinoma n243 Mucinous adenocarcinoma n37 TCGA sample Expression IRF3 COAD based patients gender Normal n41 Male n156 Female n127 TCGA sample Expression IRF3 COAD based histological subtypes Normal n41 Adenocarcinoma n243 Mucinous adenocarcinoma n37 TCGA sample Figure 2 The transcription level IRF2 A IRF3 B subgroups COAD patients stratified according following criteria race age weight sex nodal metastasis individual cancer stages TP53 mutation status histological subtypes UALCAN Data meanSE P005 P001 P0001 Metascape Results Metascape httpmetascapeorg productive gene function annotation analysis tool annotate large number genes identify enriched pathways 17 The 10 genes cor related IRFs member COAD extracted GEPIA dataset genes analyzed Metascape With GO KEGG methods able ana lyze gene list related IRFs identify frequently altered linked genes constructed proteinprotein interac tion networks lists genes proteins Expression level IRFs COAD The differences transcription levels IRFs COAD normal tissues evaluated UALCAN databas es study expression profiles IRFs COAD patients Compared normal tissues IRF3 Figure 1C P162E12 upregulated COAD tissues Figure 1 However IRF2 Figure 1B P439E12 IRF4 Figure 1D P155E08 IRF6 Figure 1F P856E04 IRF7 Figure 1G P501E03 downregulated COAD tissues relative healthy tissues significant differences transcription This work licensed Creative Common Attribution NonCommercialNoDerivatives 40 International CC BYNCND 40 e9270734 Indexed Current ContentsClinical Medicine SCI Expanded ISI Alerting System ISI Journals Master List Index MedicusMEDLINE EMBASEExcerpta Medica Chemical AbstractsCASDATABASE ANALYSIS Yuemaier M et al The role IRFs COAD Med Sci Monit 2020 26 e927073 A n o l l m r e p t p r c s n r T n o l l m r e p t p r c s n r T B n o l l m r e p t p r c s n r T n o l l m r e p t p r c s n r T C n o l l m r e p t p r c s n r T n o l l m r e p t p r c s n r T 20 15 10 5 0 5 20 15 10 5 0 5 80 70 60 50 40 30 20 10 0 80 60 40 20 0 70 60 50 40 30 20 10 0 10 60 50 40 30 20 10 0 10 Expression IRF4 COAD based patients race Expression IRF4 COAD based patients weight Expression IRF4 COAD based patients age Expression IRF4 COAD based patients gender Normal n41 Caucasian n193 African American n55 Asian n11 TCGA sample Expression IRF4 COAD based nodal metastasis status Normal n41 N0 n166 N1 n70 N2 n47 n o l l m r e p t p r c s n r T n o l l m r e p t p r c s n r T 20 15 10 5 0 5 20 15 10 5 0 5 Normal n41 Normal weight n70 Extreme weight n74 Obese n56 Extreme obese n10 TCGA sample Expression IRF4 COAD based individual cancer stages Normal n41 Stage1 n45 Stage2 n120 Stage3 n80 Stage4 n39 TCGA sample TCGA sample Expression IRF6 COAD based patients race Expression IRF6 COAD based patients weight Normal n41 Caucasian n193 African American n55 Asian n11 TCGA sample Expression IRF6 COAD based nodal metastasis status Normal n41 N0 n166 N1 n70 N2 n47 n o l l m r e p t p r c s n r T n o l l m r e p t p r c s n r T 80 70 60 50 40 30 20 10 0 80 60 40 20 0 Normal n41 Normal weight n70 Extreme weight n74 Obese n56 Extreme obese n10 TCGA sample Expression IRF6 COAD based individual cancer stages Normal n41 Stage1 n45 Stage2 n120 Stage3 n80 Stage4 n39 n o l l m r e p t p r c s n r T n o l l m r e p t p r c s n r T n o l l m r e p t p r c s n r T n o l l m r e p t p r c s n r T 20 15 10 5 0 5 20 15 10 5 0 5 70 60 50 40 30 20 10 0 80 60 40 20 0 Normal n41 2140 Yrs n12 4160 Yrs n90 6180 Yrs n149 81100 Yrs n32 TCGA sample Expression IRF4 COAD based TP53 muation status Normal n41 TP53Mutast n160 TP53NonMutant n122 TCGA sample Expression IRF6 COAD based patients age Normal n41 2140 Yrs n12 4160 Yrs n90 6180 Yrs n149 81100 Yrs n32 TCGA sample Expression IRF6 COAD based TP53 muation status Normal n41 TP53Mutast n160 TP53NonMutant n122 TCGA sample TCGA sample TCGA sample TCGA sample TCGA sample TCGA sample n o l l m r e p t p r c s n r T n o l l m r e p t p r c s n r T n o l l m r e p t p r c s n r T n o l l m r e p t p r c s n r T 20 15 10 5 0 5 20 15 10 5 0 5 70 60 50 40 30 20 10 0 80 70 60 50 40 30 20 10 0 Normal n41 Male n156 Female n127 TCGA sample Expression IRF4 COAD based histological subtypes Normal n41 Adenocarcinoma n243 Mucinous adenocarcinoma n37 TCGA sample Expression IRF6 COAD based patients gender Normal n41 Male n156 Female n127 TCGA sample Expression IRF6 COAD based histological subtypes Normal n41 Adenocarcinoma n243 Mucinous adenocarcinoma n37 TCGA sample TCGA sample Expression IRF7 COAD based patients race Expression IRF7 COAD based patients weight Expression IRF7 COAD based patients age Expression IRF7 COAD based patients gender Normal n41 Caucasian n193 African American n55 Asian n11 TCGA sample Expression IRF7 COAD based nodal metastasis status Normal n41 N0 n166 N1 n70 N2 n47 n o l l m r e p t p r c s n r T n o l l m r e p t p r c s n r T 60 50 40 30 20 10 0 10 80 60 40 20 0 20 Normal n41 Normal weight n70 Extreme weight n74 Obese n56 Extreme obese n10 TCGA sample Expression IRF7 COAD based individual cancer stages Normal n41 Stage1 n45 Stage2 n120 Stage3 n80 Stage4 n39 n o l l m r e p t p r c s n r T n o l l m r e p t p r c s n r T 60 50 40 30 20 10 0 10 60 50 40 30 20 10 0 10 Normal n41 2140 Yrs n12 4160 Yrs n90 6180 Yrs n149 81100 Yrs n32 TCGA sample Expression IRF7 COAD based TP53 muation status Normal n41 TP53Mutast n160 TP53NonMutant n122 n o l l m r e p t p r c s n r T n o l l m r e p t p r c s n r T 70 60 50 40 30 20 10 0 10 70 60 50 40 30 20 10 0 10 Normal n41 Male n156 Female n127 TCGA sample Expression IRF7 COAD based histological subtypes Normal n41 Adenocarcinoma n243 Mucinous adenocarcinoma n37 Figure 3 The transcription level IRF4 A IRF6 B IRF7 C subgroups COAD patients stratified according different criteria UALCAN Data meanSE P005 P001 P0001 e9270735 Indexed Current ContentsClinical Medicine SCI Expanded ISI Alerting System ISI Journals Master List Index MedicusMEDLINE EMBASEExcerpta Medica Chemical AbstractsCASThis work licensed Creative Common AttributionNonCommercialNoDerivatives 40 International CC BYNCND 40DATABASE ANALYSIS Yuemaier M et al The role IRFs COAD Med Sci Monit 2020 26 e927073 Methylation difference tumor normal samples Log1OFDR 5 10 15 20 25 Spearman correlation coefficient methylation gene expression COAD Cancer types Methylation Difl T N 00 01 02 A l o b m y S B l o b m y S IRF4 IRF6 IRF7 IRF8 IRF5 IRF2 IRF1 IRF6 IRF3 IRF7 IRF5 IRF8 IRF4 IRF1 Log1OFDR 5 10 15 20 COAD Cancer types Spearm correlation coefficient 05040302 Figure 4 Methylation level IRFs COAD tissues The difference IRF family methylation COAD normal specimens A Correlation IRF family methylation IRF family expression COAD B levels IRF1589 COAD healthy tissues Additionally UALCAN allowed discover relationship expression levels IRFs COAD patholog ical clinical features The boxplots indicate transcription levels IRF2 Figure 2A IRF4 Figure 3A IRF6 Figure 3B COAD patients downregulated compared normal patients subgroup analyses race age weight sex nodal metastasis individual cancer stages TP53 mutation sta tus histological subtypes In contrast IRF3 mRNA lev els Figure 2B higher COAD patients healthy persons subgroup analyses pathological clinical features There significant change IRF7 Figure 3C Interestingly expression levels IRF3 significantly different overweight male patients high er IRF3 mRNA levels Moreover nodal metastasis IRF3 levels N2 stage noticeably higher stages In TP53nonmutant type mucinous adenocarcinoma IRF3 mRNA levels distinctly upregulat ed In methylation analysis methylation levels IRFs COAD tissues elevated IRF1 regulated Figure 4A In addition methylation negative ly correlated expression IRFs COAD Figure 4B Prognostic value IRF family COAD GEPIA established prognostic value IRFs expression levels COAD patients In COAD patients high expression levels IRF37 significantly associated poor OS Figure 5A However expression level IRFs COAD patients independent DFS Figure 5B Overall elevated mRNA lev els IRF37 significantly associated poor progno sis IRF37 potential biomarkers predicting survival COAD patients Genetic variation The genetic variation IRF family COAD shown Figure 6 These variations include missense mutation splice site frameshift insertion frameshift deletion multihit non sense mutation inframe deletion Figure 6 Next role IRF family crucial cancerrelated pathways evaluated We established IRF family involved activation tumor cell apoptosis pathways hormone ER pathway We IRFs inhibit cell cycle DNA damage pathways Figure 7 Therefore genomic aber rations serve potential biomarkers drug screen ing affect clinical responses treatment Drug sensitivity analysis showed expression levels IRF248 nega tively associated drug resistance Figure 8 Immune infiltration IRF family COAD patients We TIMER web resource investigated IRFs expression related immune infiltration levels COAD Tumor purity important factor genomic approach es influences analysis immune infiltration clinical tumor samples 18 The expression levels IRF fami ly members COAD associated infiltrating immune This work licensed Creative Common Attribution NonCommercialNoDerivatives 40 International CC BYNCND 40 e9270736 Indexed Current ContentsClinical Medicine SCI Expanded ISI Alerting System ISI Journals Master List Index MedicusMEDLINE EMBASEExcerpta Medica Chemical AbstractsCASDATABASE ANALYSIS Yuemaier M et al The role IRFs COAD Med Sci Monit 2020 26 e927073 A l v v r u s t n e c r e P 10 08 06 04 02 00 Overall survival Overall survival Overall survival Overall survival Overall survival 10 08 06 04 02 00 l v v r u s t n e c r e P 10 08 06 04 02 00 l v v r u s t n e c r e P 10 08 06 04 02 00 l v v r u s t n e c r e P 10 08 06 04 02 00 l v v r u s t n e c r e P 0 100 50 Months 150 0 100 50 Months 150 0 100 50 Months 150 0 100 50 Months 150 0 100 50 Months 150 Overall survival Overall survival Overall survival Overall survival B l v v r u s t n e c r e P 10 08 06 04 02 00 0 l v v r u s t n e c r e P 10 08 06 04 02 00 0 100 50 Months 150 l v v r u s t n e c r e P 10 08 06 04 02 00 0 100 50 Months 150 l v v r u s t n e c r e P 10 08 06 04 02 00 0 100 50 Months 150 l v v r u s t n e c r e P 10 08 06 04 02 00 0 100 50 Months 150 Disease free survival Disease free survival Disease free survival Disease free survival Disease free survival 10 08 06 04 02 00 l v v r u s t n e c r e P 10 08 06 04 02 00 l v v r u s t n e c r e P 10 08 06 04 02 00 l v v r u s t n e c r e P 10 08 06 04 02 00 l v v r u s t n e c r e P 100 50 Months 150 0 100 50 Months 150 0 100 50 Months 150 0 100 50 Months 150 0 100 50 Months 150 Disease free survival Disease free survival Disease free survival Disease free survival l v v r u s t n e c r e P 10 08 06 04 02 00 0 100 50 Months 150 l v v r u s t n e c r e P 10 08 06 04 02 00 0 100 50 Months 150 l v v r u s t n e c r e P 10 08 06 04 02 00 0 100 50 Months 150 l v v r u s t n e c r e P 10 08 06 04 02 00 0 100 50 Months 150 Figure 5 The prognostic value mRNA level IRFs COAD In COAD patients upregulated IRF37 significantly related poor OS A members IRF family showed prognostic value DFS B The expression IRFs association OS COAD patients cells including neutrophils CD8 T cells dendritic cells mac rophage B cells CD4 T cells Figure 9 Table 1 In gener al results reveal relationship IRFs expression levels immune infiltration levels COAD Additionally copy number variations IRF family suppressed lev els infiltrating immune cells Figure 10 Enrichment analysis IRF family COAD We investigated potential role IRFs COAD pathogenesis development gene enrichment analy sis pathways processes 90 neighboring genes Figure 11 Table 2 IRFs vicinal genes significantly enriched molecular functions MF biological processes BP cellular component CC pathways involved interac tions GO enrichment analysis showed highly enriched signal regulation pathways including type I interferon signaling cas cade response interferongamma regulation cytokine production response tumor necrosis factor interleu kin27mediated signaling axis Figure 11A 11B Table 3 The 7 KEGG pathways IRF family members adjacent genes shown Figure 11C 11D Table 4 Among pathways RIGIlike receptorsignaling cascade viral carcino genesis HTLV1 infection transcription misregulation cancer associated development pathogene sis COAD Moreover mCODE retrieved revealed e9270737 Indexed Current ContentsClinical Medicine SCI Expanded ISI Alerting System ISI Journals Master List Index MedicusMEDLINE EMBASEExcerpta Medica Chemical AbstractsCASThis work licensed Creative Common AttributionNonCommercialNoDerivatives 40 International CC BYNCND 40DATABASE ANALYSIS Yuemaier M et al The role IRFs COAD Med Sci Monit 2020 26 e927073 0 1 2 3 4 5 6 7 IRF2 IRF7 IRF1 IRF6 IRF5 IRF9 IRF3 IRF4 IRF8 A 5 4 3 2 1 0 24 21 21 17 14 14 10 10 10 B Altered 29 100 29 samples Cancer types COAD Missense_Mulation Frame_Shift_Del Nonsense_Mulation Splice_Site Multi_Hit In_Frame_Del Frame_Shift_Ins Figure 6 The genetic variation analysis IRF family COAD A Summary plot displays genetic variation frequency variant types IRF family COAD B Waterfall plot shows genetic variation distribution IRF family COAD genetic variation classification IRF family adjacent genes participate JAK STAT signaling pathway tuberculosis Figure 11E 11F Kinase miRNA targets IRF family COAD To determine role IRFs COAD explored kinase target miRNA target IRF family COAD Table 5 The results suggested kinase LCK LYN common targets IRF14789 The kinase target IRF5 SYK FYN Kinase ATR STK kinase targets IRF6 The kinase targets IRF3 IKBKB PLK3 The miR NA targets IRFs shown Table 6 The TGTATGA MIR 175P MIR20A MIR106A MIR106B MIR20B MIR519D TGTATGA MIR4853P suggested miRNA targets IRF3 CCAGGGG MIR331 CAGTCAC MIR134 suggested miRNA targets IRF7 This work licensed Creative Common Attribution NonCommercialNoDerivatives 40 International CC BYNCND 40 e9270738 Indexed Current ContentsClinical Medicine SCI Expanded ISI Alerting System ISI Journals Master List Index MedicusMEDLINE EMBASEExcerpta Medica Chemical AbstractsCASDATABASE ANALYSIS Yuemaier M et al The role IRFs COAD Med Sci Monit 2020 26 e927073 l o b m y S IRF8 IRF7 IRF6 IRF5 IRF4 IRF3 IRF2 IRF1 25 25 29 47 0 0 0 0 0 7 13 0 25 15 6 28 4 4 21 15 16 0 25 6 18 0 13 13 13 13 15 6 6 6 3 3 3 3 0 3 7 15 13 19 6 0 13 4 16 7 10 6 15 3 12 12 Apoptosis_A Apoptosis_I Cell cycle_A EMT_A DNA Damage response_A Cell cycle_I DNA Damage response_I EMT_I Hormone AR_A Hormone AR_I Hormone ER_A Hormone ER_I PI3KAKT_A PI3KAKT_I RASMAPK_A RASMAPK_I RTK_A RTK_I Pathway A Activate I Inhibit Percent 25 0 25 Figure 7 Cancerrelated pathways analysis IRF family COAD A B log10 FDR 10 20 30 40 Spearman correlation 04 02 00 02 log10 FDR 10 20 Figure 8 A B Role IRF family members drug sensitivity A positive correlation indicates high gene expression resistant drugs vice versa Discussion The prognosis COAD mainly depends extent dis ease lack reliable biomarkers results late diagnosis high mortality COAD 19 If genetic diagnosis detect COAD early stage effective interven tion prognosis patients greatly improved The IRF family plays important function cancer immunobiol ogy During tumorigenesis member strictly controls production function cells involved antitumor im mune response 20 The diverse role IRFs cancers reported suggesting IRFs modulate tumor progres sion biomarkers However COAD specific description correlation tween IRFs COAD Firstly explored transcription level IRFs COAD IRF246 downregulated COAD patients kind clinic pathologic features IRF3 highly expressed COAD tissues IRF1589 showed result statistically significant studies showed increased IRF1 IRF2 levels CRC tissues e9270739 Indexed Current ContentsClinical Medicine SCI Expanded ISI Alerting System ISI Journals Master List Index MedicusMEDLINE EMBASEExcerpta Medica Chemical AbstractsCASThis work licensed Creative Common AttributionNonCommercialNoDerivatives 40 International CC BYNCND 40DATABASE ANALYSIS Yuemaier M et al The role IRFs COAD Med Sci Monit 2020 26 e927073 10 Purity B Cell CD8T Cell B CD4T Cell Macrophage Neutrophil Dendritc Cell D A O C D A O C D A O C D A O C D A O C D A O C D A O C 8 6 4 6 5 4 3 7 6 5 4 5 4 3 2 1 0 5 4 3 2 1 7 6 5 4 6 4 2 6 025 050 075 10000 01 02 03 04 00 02 04 06 00 01 02 03 04 00 01 02 03 01 02 03 03 06 09 Purity B Cell CD8T Cell Infiltration level CD4T Cell Macrophage Neutrophil Dendritc Cell 025 050 075 10000 01 02 03 04 00 02 04 06 00 01 02 03 04 00 01 02 03 01 02 03 03 06 09 Infiltration level Purity B Cell CD8T Cell CD4T Cell Macrophage Neutrophil Dendritc Cell 025 050 075 10000 01 02 03 04 00 02 04 06 00 01 02 03 04 00 01 02 03 01 02 03 03 06 09 Infiltration level Purity B Cell CD8T Cell CD4T Cell Macrophage Neutrophil Dendritc Cell 025 050 075 10000 01 02 03 04 00 02 04 06 00 01 02 03 04 00 01 02 03 01 02 03 03 06 09 Infiltration level Purity B Cell CD8T Cell CD4T Cell Macrophage Neutrophil Dendritc Cell 025 050 075 10000 01 02 03 04 00 02 04 06 00 01 02 03 04 00 01 02 03 01 02 03 03 06 09 Infiltration level Purity B Cell CD8T Cell CD4T Cell Macrophage Neutrophil Dendritc Cell 025 050 075 10000 01 02 03 04 00 02 04 06 00 01 02 03 04 00 01 02 03 01 02 03 03 06 09 Infiltration level Purity B Cell CD8T Cell CD4T Cell Macrophage Neutrophil Dendritc Cell 025 050 075 10000 01 02 03 04 00 02 04 06 00 01 02 03 04 00 01 02 03 01 02 03 03 06 09 Infiltration level Purity B Cell CD8T Cell CD4T Cell Macrophage Neutrophil Dendritc Cell D A O C 4 2 This work licensed Creative Common Attribution NonCommercialNoDerivatives 40 International CC BYNCND 40 e92707310 Infiltration level 025 050 075 10000 01 02 03 04 00 02 04 06 00 01 02 03 04 00 01 02 03 01 02 03 03 06 09 Purity B Cell CD8T Cell CD4T Cell Macrophage Neutrophil Dendritc Cell D A O C 8 7 6 5 4 3 025 050 075 10000 01 02 03 04 00 02 04 06 00 01 02 03 04 00 01 02 03 01 02 03 03 06 09 Infiltration level A B C D E F G M P T 2 g o l l e v e l n o s s e r p x E 1 F R I M P T 2 g o l l e v e l n o s s e r p x E 2 F R I M P T 2 g o l l e v e l n o s s e r p x E 3 F R I M P T 2 g o l l e v e l n o s s e r p x E 4 F R I M P T 2 g o l l e v e l n o s s e r p x E 5 F R I M P T 2 g o l l e v e l n o s s e r p x E 6 F R I M P T 2 g o l l e v e l n o s s e r p x E 7 F R I M P T 2 g o l l e v e l n o s s e r p x E 8 F R I M P T 2 g o l l e v e l n o s s e r p x E 9 F R I Indexed Current ContentsClinical Medicine SCI Expanded ISI Alerting System ISI Journals Master List Index MedicusMEDLINE EMBASEExcerpta Medica Chemical AbstractsCASDATABASE ANALYSIS M P T 2 g o l l e v e l n o s s e r p x E 1 F R I M P T 2 g o l l e v e l n o s s e r p x E 2 F R I M P T 2 g o l l e v e l n o s s e r p x E 3 F R I M P T 2 g o l l e v e l n o s s e r p x E 4 F R I M P T 2 g o l l e v e l n o s s e r p x E 5 F R I M P T 2 g o l l e v e l n o s s e r p x E 6 F R I 10 D A O C 8 6 4 6 5 4 3 7 6 5 4 5 4 3 2 1 0 5 4 3 2 1 7 6 5 4 D A O C D A O C D A O C D A O C D A O C Purity B Cell CD8T Cell CD4T Cell Macrophage Neutrophil Dendritc Cell 025 050 075 10000 01 02 03 04 00 02 04 06 00 01 02 03 04 00 01 02 03 01 02 03 03 06 09 Purity B Cell CD8T Cell Macrophage Neutrophil Dendritc Cell 025 050 075 10000 01 02 03 04 00 02 04 06 00 01 02 03 04 00 01 02 03 01 02 03 03 06 09 Purity B Cell CD8T Cell CD4T Cell Macrophage Neutrophil Dendritc Cell 025 050 075 10000 01 02 03 04 00 02 04 06 00 01 02 03 04 00 01 02 03 01 02 03 03 06 09 Purity B Cell CD8T Cell CD4T Cell Macrophage Neutrophil Dendritc Cell 025 050 075 10000 01 02 03 04 00 02 04 06 00 01 02 03 04 00 01 02 03 01 02 03 03 06 09 Purity B Cell CD8T Cell CD4T Cell Macrophage Neutrophil Dendritc Cell 025 050 075 10000 01 02 03 04 00 02 04 06 00 01 02 03 04 00 01 02 03 01 02 03 03 06 09 Purity B Cell CD8T Cell CD4T Cell Macrophage Neutrophil Dendritc Cell 025 050 075 10000 01 02 03 04 00 02 04 06 00 01 02 03 04 00 01 02 03 01 02 03 03 06 09 Infiltration level CD4T Cell Infiltration level Infiltration level Infiltration level Infiltration level Infiltration level B Cell CD8T Cell CD4T Cell Macrophage Neutrophil Dendritc Cell Yuemaier M et al The role IRFs COAD 6 Med Sci Monit 2020 26 e927073 M P T 2 g o l Purity l e v e l H I n o s s e r p x E 7 F R I M P T 2 g o l l e v e l n o s s e r p x E 8 F R I M P T 2 g o l l e v e l n o s s e r p x E 9 F R I 025 050 075 10000 01 02 03 04 00 02 04 06 00 01 02 03 04 00 01 02 03 01 02 03 03 06 09 Infiltration level Purity B Cell CD8T Cell CD4T Cell Macrophage Neutrophil Dendritc Cell 025 050 075 10000 01 02 03 04 00 02 04 06 00 01 02 03 04 00 01 02 03 01 02 03 03 06 09 Infiltration level Purity B Cell CD8T Cell CD4T Cell Macrophage Neutrophil Dendritc Cell D A O C D A O C D A O C 4 2 6 4 2 8 7 6 5 4 3 025 050 075 10000 01 02 03 04 00 02 04 06 00 01 02 03 04 00 01 02 03 01 02 03 03 06 09 Infiltration level Figure 9 Correlation IRFs expression immune infiltration level COAD tissues TIMER The scatter plots AI identify different profiles immune cells associated IRFs Table 1 Comparison gene expression immune cell landscape Tumor purity B cells CD8T cells CD4T cells Macrophages Neutrophils Dendritic cells IRF1 IRF2 IRF3 IRF4 IRF5 IRF6 IRF7 IRF8 IRF9 r r r r r r r Correlation immune cell landscape COAD compared TCGA gene expression IRFs TIMER r categorized Pearsons correlation coefficient 05 03 weak negative association 03 01 little association 01 03 little association 03 05 weak positive association 05 10 strong positive association high expression level IRF2 related 2fold increase risk allcause mortality CRC pa tients 2122 Although IRF7 downregulated COAD tis sues IRF3 IRF7 significantly associated poorer overall survival These data indicate differentially ex pressed IRFs play significant role COAD As recent study suggests bcatenin overexpressed colorectal cer expression level positively associated level IRF3 CRC cells 23 The present study demonstrates molecular characteristics IRFs COAD In COAD frequent genetic alterations IRFs differentially expressed Genomic aberrations serve potential biomarkers drug screening affect clinical responses treatment Drug sensitivity analysis shows expression levels IRF248 negatively associated drug resistance indicating potential novel markers drug screening Next focused immune cell infiltration Interestingly COAD patients IRF357 weak correlation B cells CD8 T cells infiltration level IRF124689 showed strong correlation infiltration levels 6 types immune cells neutrophils CD8 T cells dendritic e92707311 Indexed Current ContentsClinical Medicine SCI Expanded ISI Alerting System ISI Journals Master List Index MedicusMEDLINE EMBASEExcerpta Medica Chemical AbstractsCASThis work licensed Creative Common AttributionNonCommercialNoDerivatives 40 International CC BYNCND 40DATABASE ANALYSIS Yuemaier M et al The role IRFs COAD Med Sci Monit 2020 26 e927073 A l e v e l n o t r t l fi n I C l e v e l n o t r t l fi n I E l e v e l n o t r t l fi n I 15 10 05 00 15 10 05 00 15 10 05 00 G l e v e l n o t r t l fi n I 15 10 05 00 COAD B Cell CD8 T Cell B CD4 T Cell Macrophage Neutrophil Dendritic Cell COAD B Cell CD8 T Cell B CD4 T Cell Macrophage Neutrophil Dendritic Cell COAD B Cell CD8 T Cell B CD4 T Cell Macrophage Neutrophil Dendritic Cell COAD B Copy number Deep delection Armlevel deletion DiploidNormal Armlevel gain D Copy number Armlevel deletion DiploidNormal Armlevel gain F Copy number Armlevel deletion DiploidNormal Armlevel gain High amplication H Copy number Deep delection Armlevel deletion DiploidNormal Armlevel gain l e v e l n o t r t l fi n I l e v e l n o t r t l fi n I l e v e l n o t r t l fi n I l e v e l n o t r t l fi n I 15 10 05 00 15 10 05 00 15 10 05 00 15 10 05 00 COAD B Cell CD8 T Cell B CD4 T Cell Macrophage Neutrophil Dendritic Cell COAD B Cell CD8 T Cell B CD4 T Cell Macrophage Neutrophil Dendritic Cell COAD B Cell CD8 T Cell B CD4 T Cell Macrophage Neutrophil Dendritic Cell COAD Copy number Deep delection Armlevel deletion DiploidNormal Armlevel gain High amplication Copy number Deep delection Armlevel deletion DiploidNormal Armlevel gain High amplication Copy number Armlevel deletion DiploidNormal Armlevel gain High amplication Copy number Deep delection Armlevel deletion DiploidNormal Armlevel gain B Cell CD8 T Cell B CD4 T Cell Macrophage Neutrophil Dendritic Cell B Cell CD8 T Cell B CD4 T Cell Macrophage Neutrophil Dendritic Cell I l e v e l n o t r t l fi n I 15 10 05 00 COAD Copy number Armlevel deletion DiploidNormal Armlevel gain B Cell CD8 T Cell B CD4 T Cell Macrophage Neutrophil Dendritic Cell Figure 10 AI Effect copy number variation IRF gene family level immune cell infiltration cells macrophage B cells CD4 T cells change copy number IRF family inhibits level infiltrating immune cells Unlike IRF members IRF3 expression weak correlation infiltration levels B cells CD8 T cells neutrophils macrophages dendritic cells significant correlation CD4T cells infiltration level COAD patients Studies revealed compared normal colon tissues CD4T cells colorec tal cancer tissues 24 correlation IRF3 CD4 T cells suggested role biomarker IRF3 COAD With GO enrichment analysis KEGG pathway enrichment analysis potential role IRFs COAD develop ment The IRF family enriched type I inter feron signaling cascade expected expect IRF6 members primary regulator type I IFN activation The type I IFN signaling pathway im portant innate antiviral immunity pathway damage related increased risk tumorigenesis IRF9 enhance p53 pathway cells exposed endogenous duced exogenous type I interferon suggesting IRF9 This work licensed Creative Common Attribution NonCommercialNoDerivatives 40 International CC BYNCND 40 e92707312 Indexed Current ContentsClinical Medicine SCI Expanded ISI Alerting System ISI Journals Master List Index MedicusMEDLINE EMBASEExcerpta Medica Chemical AbstractsCASDATABASE ANALYSIS Yuemaier M et al The role IRFs COAD Med Sci Monit 2020 26 e927073 A B GO 0060337 type I interferon signaling pathway GO 0034341 response interferongamma GO0001817 regulation cytokine production GO 0034612 respone tumor necrosis factor GO 0070106 interleukin27mediated signaling pathway GO0050856 regulation T cell receptor signaling pathway GO 2001034 positive regulation doublestrand break repair nonhomologous end joining GO 0097191 extrinsic apoptotic signaling pathway GO 0003725 doublestanded RNA binding GO 0046777 protein autophosphorylation GO 1905476 negative regulation protein localization membrane GO 0035456 response interferonbeta GO 0002683 negative regulation immune process GO 0006302 doublestrand break repair GO 0030155 regulation cell adhesion GO 0051603 proteolysis involved cellular protein catabolic process GO 0042803 protein homodimerization activity GO 0046579 positive regulation Ras protein signaling transduction GO 0002479 antigen processing presentation exogenous peptide antigen MHC class I TAPdependent GO 2001252 positive regulation chromosome organization D hsa05168 Herpes simplex infection hsa04622 RIGI_like receptor signaling pathway hsa05203 Viral carcinogenesis hsa05202 Transcriptional misregulation cancer hsa04142 Lysosome hsa04114 Oocyte meiosis hsa05166 HTLVI infection 0 2 4 6 8 10 12 14 16 log10 P C 0 2 4 6 8 10 12 log10 P E F Color MCODE GO Description Log10 P MCODE_1 hsa_M00684 JAKSTAT signaling MCODE_1 M00684 JAKSTAT signaling MCODE_1 hsa05152 Tuberculosis 81 81 74 Figure 11 Functional enrichment analysis IRFs COAD Metascape A B The enriched terms GO analysis colored P value C D The enriched terms KEGG pathways analysis colored P values E PPI network 3 significant MCODE components F Independent functional enrichment analysis 3 MCODE components antiproliferation effect 720 Results showed IRFs mainly associated response tumor necrosis factor transcription misregulation cancer JAKSTAT signaling pathway The JAKSTAT pathway com mon signal transduction pathway pathological ditions activation pathway associated proliferation malignant tumors 25 An immunohis tochemical experiment showed expression levels JAK1 STAT3 proteins upregulated colon cancer tissues levels independent risk factor prognosis colon cancer 26 As study showed IRFs closely related JAKSTAT pathway suggests high expression level IRF37 COAD patients deeper relationship JAKSTAT signaling pathway tumor development Finally different interactions IRFs SRC fam ily tyrosine kinases LCK LYN FYN play different roles e92707313 Indexed Current ContentsClinical Medicine SCI Expanded ISI Alerting System ISI Journals Master List Index MedicusMEDLINE EMBASEExcerpta Medica Chemical AbstractsCASThis work licensed Creative Common AttributionNonCommercialNoDerivatives 40 International CC BYNCND 40DATABASE ANALYSIS Yuemaier M et al The role IRFs COAD Med Sci Monit 2020 26 e927073 Table 2 Top 10 correlated genes member IRF family COAD GEPIA IRF1 IRF2 IRF3 IRF4 IRF5 IRF6 IRF7 IRF8 IRF9 UBE2L6 GBP1 TAP1 STAT1 C5orf56 GBP4 PSMB9 PARP14 ETV7 SAMD9L CASP3 CAMK2D ATP10D CYLD TLR3 CTSO TNFSF10 LITAF JAK1 JAK2 PNKP SNRNP70 PTOV1AS2 AC0187664 LENG1 SMG9 PRKD2 SUV420H2 CLASRP PPP1R12C LAX1 PRR33 GPR174 KCNA3 CTD2020K171 ZNF80 TRAF3IP3 RP11686D2210 NCF1B UBASH3A AP1M1 GDI1 C17orf62 RP111072A33 IKBKG TFE3 SCPEP1 MAP3K3 TBC1D25 SAMHD1 LPGAT1 C1orf106 PLEKHA6 F11R KDM5B PPP2R5A ETV3 BROX GOLPH3L PIK3C2B XAF1 MX1 ISG15 IFIT1 OAS2 IFI44 IRF9 DHX58 HSH2D AP0016105 NUB1 RP11542M132 MCM4 NBN MAX IMPA1 SSX2IP TCEA1P2 CDC27 TRAF3 PARP9 XAF1 OAS2 DDX60 SP100 PARP14 IFI44 IFIT3 SP110USP1 Table 3 GO function enrichment analysis IRF family members neighbor genes COAD Metascape GO Category Description Count Log10P Log10q GO 0060337 GO biological processes Type I interferon signaling pathway GO 0034341 GO biological processes Response interferongamma GO 0001817 GO biological processes Regulation cytokine production GO 0034612 GO biological processes Response tumor necrosis factor GO 0070106 GO biological processes GO 0050856 GO biological processes GO 2001034 GO biological processes Interleukin27mediated signaling pathway Regulation T cell receptor signaling pathway Positive regulation doublestrand break repair nonhomologous joining GO 0097191 GO biological processes Extrinsic apoptotic signaling pathway GO 0003725 GO Molecular Functions Doublestranded RNA binding GO 0046777 GO biological processes Protein autophosphorylation GO 1905476 GO biological processes Negative regulation protein localization membrane GO 0035456 GO biological processes Response interferonbeta GO 0002683 GO biological processes Negative regulation immune process GO 006302 GO biological processes Doublestrand break repair GO 0030155 GO biological processes Regulation cell adhesion GO 0051603 GO biological processes Proteolysis involved cellular protein catabolic process GO 0042803 GO Molecular Functions Protein homodimerzation activity GO 0046579 GO biological processes GO 0002479 GO biological processes GO 2001252 GO biological processes Positive regulation RAS protein signal transduction Antigen processing presentation exogenous peptide antigen MHC class I TAPdependent Positive regulation chromosome organization 12 13 15 9 3 4 3 6 4 6 3 3 8 6 9 9 8 3 3 4 1558 1570 1173 1688 1312 1948 1169 787 614 961 469 309 390 530 242 519 514 234 390 477 202 779 519 779 409 401 397 144 137 136 390 393 133 390 388 131 1039 382 127 779 1169 374 335 121 090 1169 329 087 1039 298 062 390 287 054 390 275 046 519 254 034 This work licensed Creative Common Attribution NonCommercialNoDerivatives 40 International CC BYNCND 40 e92707314 Indexed Current ContentsClinical Medicine SCI Expanded ISI Alerting System ISI Journals Master List Index MedicusMEDLINE EMBASEExcerpta Medica Chemical AbstractsCASDATABASE ANALYSIS Yuemaier M et al The role IRFs COAD Med Sci Monit 2020 26 e927073 Table 4 KEGG function enrichment analysis IRF family members neighbor genes COAD Metascape Items Category Description hsa05168 KEGG pathway Herpes simplex inflection hsa04622 KEGG pathway RIGIlike receptor signaling pathway hsa05203 KEGG pathway Viral cacinogenesis hsa05202 KEGG pathway Transcriptional misregulation cancer hsa04142 KEGG pathway Lysosome hsa04114 KEGG pathway Oocyte meiosis hsa05166 KEGG pathway HTLVI infection Table 5 Kinase target networks IRF family COAD Count 12 5 6 4 3 3 4 Log10P Log10q 1558 1217 649 779 519 390 390 519 553 435 258 214 214 204 948 361 256 123 087 087 081 Enriched kinase target Description Leading edge num P value IRFs IRF1 Kinase_LCK Kinase_LYN IRF2 Kinase_LCK LCK protooncogene Src family tyrosine Kinase LYN protooncogene Src family tyrosine Kinase LCK protooncogene Src family tyrosine Kinase Kinase_SYK spleen associated tyrosine Kinase IRF3 Kinase_IKBKB Inhibitor nuclear factor Kappa B Kinase subunit bata Kinase_PLK3 polo like Kinase 3 IRF4 Kinase_LCK Kinase_LYN LCK protooncogene Src family tyrosine Kinase LYN protooncogene Src family tyrosine Kinase IRF5 Kinase_SYK Spleen associated tyrosine Kinase Kinase_FYN FYN protooncogene Src family tyrosine Kinase IRF6 Kinase_ATR ATR serinethreonine Kinase Kinase_STK4 serinethreonine Kinase IRF7 Kinase_LYN Kinase_LCK IRF8 Kinase_LYN Kinase_LCK IRF9 Kinase_LYN Kinase_LCK LYN protooncogene Src family tyrosine Kinase LCK protooncogene Src family tyrosine Kinase LYN protooncogene Src family tyrosine Kinase LCK protooncogene Src family tyrosine Kinase LYN protooncogene Src family tyrosine Kinase LCK protooncogene Src family tyrosine Kinase e92707315 25 26 24 18 6 5 22 22 22 31 30 5 20 28 27 21 21 25 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Indexed Current ContentsClinical Medicine SCI Expanded ISI Alerting System ISI Journals Master List Index MedicusMEDLINE EMBASEExcerpta Medica Chemical AbstractsCASThis work licensed Creative Common AttributionNonCommercialNoDerivatives 40 International CC BYNCND 40DATABASE ANALYSIS 42 44 25 44 229 63 166 152 67 46 53 0 0 0 0 0 0 0042 0060 0002 0002 0 0 0 0 0 0 0 0 Yuemaier M et al The role IRFs COAD Med Sci Monit 2020 26 e927073 Table 6 miRNA target networks IRF family COAD Enriched miRNA target Leading edge num P value IRFs IRF1 GTATTAT MIR3693p CTTGTA MIR381 IRF2 GTGTTGA MIR505 GCACCTT MIR18A MIR18B IRF3 GCACTTT MIR175P MIR20A MIR106A MIR106BMIR20B MIR519D TGTATGA MIR4853P IRF4 CAGTATT MIR200B MIR200C MIR429 ACTGTGA MIR27A MIR27B IRF5 ATGCTGC MIR103 MIR107 TCCAGAG MIR518C IRF6 GACAATC MIR219 GCACTTT MIR175P MIR20A MIR106A MIR106B MIR20B MIR519D 203 IRF7 CCAGGGG MIR331 CAGTCAC MIR134 IRF8 CACTTTG MIR520G MIR520H AAGCAAT MIR137 IRF9 CCAGGTT MIR490 TATCTGG MIR488 21 17 43 57 21 16 oncogenesis The common kinase targets IRF14789 LCK LYN LCK important tumorigenesis expression level LCK elevated colorectal cancer cells suggesting LCK cancerpromoting role CRC 2728 As common kinase target IRF56 SYK cancer suppressor colorectal cancer 29 PLK3 kinase target IRF3 contributes regulation cell proliferation apoptosis studies showed PLK3 overexpressed breast ovarian cancer little evidence role PLK3 COAD 30 The miRNA targets IRF3 upregulated human colon cer For example MIR175p MIR20a highly ex pressed colon cancer tissues MIR106 family closely involved initiation devel opment colorectal cancer 3132 On contrary miR NA target IRF7 MIR331 reported tumor sup pressor colorectal carcinoma 33 public databases influencing factors size location tumor medical parameters incomplete influence results Since IRFs correlated cell cycle control apop tosis carcinogenesis immune responses studies needed elucidate molecular mechanism involved Conclusions Overall results indicate IRF3 IRF7 prognos tic biomarkers COAD IRF family members associat ed immune cell infiltration gene regulation networks These results add growing evidence significant role IRFs COAD contribute developing prog nostic value IRFs COAD Conflict interests This study systematically demonstrate sociation IRF family COAD limitations Because information obtained None This work licensed Creative Common Attribution NonCommercialNoDerivatives 40 International CC BYNCND 40 e92707316 Indexed Current ContentsClinical Medicine SCI Expanded ISI Alerting System ISI Journals Master List Index MedicusMEDLINE EMBASEExcerpta Medica Chemical AbstractsCASDATABASE ANALYSIS Yuemaier M et al The role IRFs COAD Med Sci Monit 2020 26 e927073 References 1 Bray F Ferlay J Soerjomataram I et al Global cancer statistics 2018 GLOBOCAN estimates incidence mortality worldwide 36 cers 185 countries published correction appears Cancer J Clin 2020 704 313 Cancer J Clin 2018 686 394424 2 Reddy BS Diet colon cancer Evidence human animal model studies In diet nutrition cancer A critical evaluation Macronutrients Cancer 1986 1 4765 3 Edwards BK Ward E Kohler BA et al Annual report nation status cancer 19752006 featuring colorectal cancer trends impact interventions risk factors screening treatment reduce future rates Cancer 2010 1163 54473 4 Zhong W Yu Z Zhan J et al Association serum levels CEA CA199 CA125 CYFRA211 CA724 disease characteristics colorectal cer Pathol Oncol Res 2015 211 83 doi 101007s1225301497919 5 Shibutani M Maeda K Nagahara H et al Significance CEA CA199 combination prognostic indicator recurrence monitoring pa tients stage II colorectal cancer Anticancer Res 2014 347 375358 6 Mancino A Natoli G Specificity function IRF family transcription fac tors Insights genomics J Interferon Cytokine Res 2016 367 46269 7 Chen YJ Li J Lu N Shen XZ Interferon regulatory factors A key tumour immunity Int Immunopharmacol 2017 49 15 8 Yanai H Negish H Taniguchi T The IRF family transcription factors Inception impact implications oncogenesis Oncoimmunology 2012 18 137686 9 Vaughan PS van der Meijden CM Aziz F et al Cell cycle regulation tone H4 gene transcription requires oncogenic factor IRF2 J Biol Chem 1998 2731 19499 10 Chae M Kim K Park SM et al IRF2 regulates NFkappaB activity mod ulating subcellular localization NFkappaB Biochem Biophys Res Commun 2008 3703 51924 11 Chandrashekar DS Bashel B Balasubramanya SAH et al UALCAN A por tal facilitating tumor subgroup gene expression survival analyses Neoplasia 2017 198 64958 12 Tang Z Li C Kang B et al GEPIA A web server cancer normal gene expression profiling interactive analyses Nucleic Acids Res 2017 45W1 W98102 13 Zeng Q Sun S Li Y et al Identification therapeutic targets prognos tic biomarkers CXC chemokines renal cell carcinoma micro environment Front Oncol 2020 9 1555 14 Mayakonda A Koeffler HP Maftools Efficient analysis visualization summarization MAF files largescale cohortbased cancer studies BioRxiv 2016 5 052662 15 Li T Fan J Wang B et al TIMER A web server comprehensive analysis tumorinfiltrating immune cells Cancer Res 2017 7721 e10810 16 Vasaikar SV Straub P Wang J Zhang B LinkedOmics Analyzing multiomics data 32 cancer types Nucleic Acids Res 2018 46D1 D95663 17 Zhou Y Zhou B Pache L et al Metascape provides biologistoriented source analysis systemslevel datasets Nat Commun 2019 101 1523 18 Yoshihara K Shahmoradgoli M Martnez E et al Inferring tumour purity stromal immune cell admixture expression data Nat Commun 2013 4 2612 19 Yang Y Li XJ Li P Guo XT MicroRNA145 regulates proliferation migra tion invasion human primary colon adenocarcinoma cells target ing MAPK1 Int J Mol Med 2018 426 317180 20 Savitsky D Tamura T Yanai H Taniguchi T Regulation immunity onco genesis IRF transcription factor family Cancer Immunol Immunother 2010 594 489510 21 Hong M Zhang Z Chen Q et al IRF1 inhibits proliferation metas tasis colorectal cancer suppressing RASRAC1 pathway Cancer Manag Res 2018 11 36978 22 Mei Z Wang G Liang Z et al Prognostic value IRF2 expression colorec tal cancer Oncotarget 2017 824 3896977 23 Ding C He J Zhao J et al bcatenin regulates IRF3mediated innate immune signalling colorectal cancer Cell Prolif 2018 515 e12464 24 Toor SM Murshed K AlDhaheri M et al Immune checkpoints circulat ing tumorinfiltrating CD4 T cell subsets colorectal cancer patients Front Immunol 2019 10 2936 25 Cui C Cheng X Yan L et al Downregulation TfR1 promotes progression colorectal cancer JAKSTAT pathway Cancer Manag Res 2019 11 632341 26 Tang S Yuan X Song J et al Association analyses JAKSTAT signaling pathway progression prognosis colon cancer Oncol Lett 2019 171 15964 27 Nakamura K Chijiiwa Y Nawata H Augmented expression LCK message directed downstream promoter human colorectal cancer speci mens Eur J Cancer 1996 32A8 14017 28 Janikowska G Janikowski T PykaPajk A et al Potential biomarkers early diagnosis colorectal adenocarcinoma transcriptomic analy sis clinical stages Cancer Biomark 2018 221 8999 29 Yang Z Huo L Chen H et al Hypermethylation prognostic implication Syk gene human colorectal cancer Med Oncol 2013 302 586 30 Helmke C Becker S Strebhardt K The role Plk3 oncogenesis Oncogene 2016 352 13547 31 Motoyama K Inoue H Takatsuno Y et al Over underexpressed mi croRNAs human colorectal cancer Int J Oncol 2009 344 106975 32 Peng Q Shen Y Zhao P et al Biomarker roles identification miR106 family predicting risk poor survival colorectal cancer BMC Cancer 2020 201 506 33 Zhang H Wang R Wang M miR3313p suppresses cell invasion mi gration colorectal carcinoma directly targeting NRP2 Oncol Lett 2019 186 65018 e92707317 Indexed Current ContentsClinical Medicine SCI Expanded ISI Alerting System ISI Journals Master List Index MedicusMEDLINE EMBASEExcerpta Medica Chemical AbstractsCASThis work licensed Creative Common AttributionNonCommercialNoDerivatives 40 International CC BYNCND 40DATABASE ANALYSIS